http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0df3e227c419d4101ecbd357186a596e
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Bergwelt-Baildon von Bergwelt-Baildon |
| name | Michael von Bergwelt-Baildon |
| given-name | Michael Michael von |
| organization-name | Department of Internal Medicine I, University of Cologne, Cologne, Germany 1Department of Medicine III, Hematology/Oncology, University Hospital, Ludwig-Maximilians Universität (LMU) Munich, Munich, Germany; 3German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany Department of Internal Medicine III, Ludwig Maximilians University, 81377 Munich, Germany Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-Universität München, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany Department of Medicine III, University Hospital, Munich, Germany Medizinische Klinik und Poliklinik III, Klinikum der Universität München, LMU München, München, Deutschland 1Cologne Interventional Immunology (CII), Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular... First Department of Internal Medicine, University of Cologne, D-50937 Cologne, Germany. Cologne Interventional Immunology, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology (CIO), University Hospital of Cologne, Cologne, Germany Department of Medicine III and Comprehensive Cancer Center, University Hospital, Ludwig Maximilian University of Munich, Marchioninistr. 15, 81377 Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, 80336 Munich, Germany From the Department of Neurosurgery (P.K., J.B., J.-C.T., L.B.), University Hospital, LMU (Ludwig-Maximilians-University) Munich; German Cancer Consortium (DKTK) (P.K., K.R., V.B., C.S., J.B., M.B.-B., J.-C.T., M.S., L.B.), Partner Site Munich; Department of Medicine III - Hematology/Oncology (K.R., V.L.B., V.B., C.S., M.B.-B., M.S.), University Hospital, LMU (Ludwig-Maximilians-University) Munich; Department of Radiology (M.W., W.G.K.), University Hospital, LMU (Ludwig-Maximilians-University)... Department of Medicine III, University Hospital, LMU Munich, Germany; German Cancer Consortium (DKTK), partner site Munich, Germany; Intensive Care in Hematologic and Oncologic Patients (iCHOP), Cologne, Germany; Comprehensive Cancer Center Munich (CCCM), Germany. Medizinische Klinik und Poliklinik III, Campus Großhadern (LMU), Klinikum der Universität München, Deutschland Intensive Care in Hematologic and Oncologic Patients, Munich, Germany; and; Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Munich, Germany Cologne Interventional Immunology, Department I of Internal Medicine, University of Cologne, Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany; Department of Medicine III, University Hospital, LMU Munich, Germany; Department of Otorhinolaryngology, Head and Neck Surgery, Georg August University, Goettingen, Germany; Partner Site, German Cancer Consortium (DKTK), Munich, Germany Cologne Interventional Immunology (CII), Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany 1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany.; 3Cologne Interventional Immunology, University Hospital Cologne, Cologne, Germany.; 10Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne; University Hospital Bonn, Bonn, Germany. Cologne Interventional Immunology, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany Department of Medicine III – Hematology/Oncology, University Hospital, LMU Munich, Germany; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany; Bavarian Cancer Research Center (BZKF), Partner Sites Munich and Erlangen, Germany Centre of Integrated Oncology Köln, University of Cologne, Germany; Department I of Internal Medicine, University of Cologne, Germany Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany; Department of Medicine III, LMU University Hospital, Munich, Germany; German Cancer Consortium (DKTK), partner site Munich, Germany Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany Medizinische Klinik und Poliklinik III, Ludwig-Maximilians-Universität München, München Medizinische Klinik und Poliklinik III am Klinikum der LMU München, GERMANY Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität München , Munich, Germany; COVID-19 Registry of the LMU Munich (CORKUM), University Hospital, Ludwig-Maximilians-Universität München , Munich, Germany; German Cancer Consortium (DKTK) , Munich, Germany Cologne Interventional Immunology, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Straße 62, D-50937, Cologne, Germany; Stem Cell Transplantation Program, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Straße 62, D-50937, Cologne, Germany Department of Medicine III, University Hospital, LMU-Munich, Munich, Germany Molecular Tumor Biology, and Tumor Immunology, University of Cologne, Cologne, Germany 1Gene Center, Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, Munich, Germany.; 2Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany.; 6German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany. Department of Medicine III, University Hospital, LMU Munich, Germany; COVID-19 Registry of the LMU Munich (CORKUM), University Hospital, LMU Munich, Germany; German Cancer Consortium (DKTK), Munich, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany Max Eder Junior Research Group and Stem Cell Transplantation Program Department I of Internal Medicine University Hospital of Cologne, Cologne, Germany Department of Internal Medicine III, Grosshadern University Hospital, Ludwig- Maximilians-University , Munich, Germany; German Cancer Consortium (DKTK), partner site , Munich, Germany Department of Medicine III, and; German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany; and Radio-Immune-Oncology (RIO) Consortium, University Hospital Cologne, Germany; Department I for Internal Medicine, Center for Integrated Oncology (CIO) Köln Bonn, University Hospital Cologne, Cologne Germany; Cologne Interventional Immunology (CII), Department I for Internal Medicine, University Hospital Cologne, Germany Department of Medicine III, Ludwig-Maximilians-University (LMU) University Hospital Munich, 81377 Munich, Germany From the Molecular Tumor Biology and Tumor Immunology, University of Cologne, Cologne, Germany; Clinic I for Internal Medicine, University of Cologne, Cologne, Germany; and Institute for Molecular Medicine and Experimental Immunology, University of Bonn, Bonn, Germany. Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-Universität München, Munich, Germany 1Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany;; 3German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany; 1Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.; 3Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany.; 4Department I of Internal Medicine I, University of Cologne, Cologne, Germany.; 5German Cancer Consortium (DKTK), Heidelberg, Germany.; 6Comprehensive Cancer Center Munich (CCCM), Munich, Germany. Department of Medicine III, University Hospital, LMU Munich, Munich, Germany;; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Munich, Germany; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; COVID-19 Registry of the LMU Munich (CORKUM), University Hospital, LMU Munich, Munich, Germany German Center for Translational Cancer Research (DKTK), partner site Munich, Germany; Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany *Cologne Interventional Immunology, Department I of Internal Medicine, University Hospital Cologne, 50937 Köln, Germany; and University Hospital of Cologne, Cologne, Germany University of Cologne Medical Faculty, Molecular Tumorbiology and Immunology, 1st Department for Internal Medicine, Kerpener Str. 62, 50924 Cologne, Germany. Cologne Interventional Immunology, University Hospital of Cologne , Cologne , Germany; Department I of Internal Medicine, University Hospital of Cologne , Cologne , Germany University Hospital of Cologne; Department I of Internal Medicine, Stem Cell Transplantation Program; Kerpener Str. 62 Cologne Germany 50924 University Hospital of Cologne; Department I of Internal Medicine, Stem Cell Transplantation Program; Cologne Germany 50924 Working Party Intensive Care in Haematologic and Oncologic Patients (iCHOP) of the German Society of Haematology and Medical Oncology (DGHO); Department of Internal Medicine III, LMU University Hospital, DKTK Partner Site Munich, BZKF Partner Site Munich, CCC-Munich, Munich, Germany. Department I of Internal Medicine, Stem Cell Transplantation Program, University Hospital of Cologne, Laboratory for Tumor and Transplantation Immunology, University of Cologne, Cologne, Germany German Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center (DKFZ) , Heidelberg , Germany; Department of Medicine III, University Hospital, LMU Munich , Munich , Germany; Bavarian Cancer Research Center (BZKF) , Erlangen , Germany Molecular Tumor Biology and Tumor Immunology, Clinic I of Internal Medicine, Hematology/Oncology, Kerpener Str 62, 50924 Köln, Germany. joachim.schultze@medizin.uni-koeln.de. Medizinische Klinik und Poliklinik III, LMU München, München, GERMANY From the Departments of Radiology (M.F., C.B.) and Internal Medicine (H.C.R., M.v.B.B.), University Hospital Cologne, Cologne, Germany. 1Department of Medicine III, University Hospital, Ludwig Maximilian University (LMU) Munich, Munich, Germany; Department of Medicine III, University Hospital, LMU Munich, Germany; Comprehensive Cancer Center München-LMU (CCCM), LMU Munich, Germany 1Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.; 3Gene Center, Ludwig Maximilians University, Munich, Germany.; 10Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; 11German Cancer Consortium (DKTK), Heidelberg, Germany. Medizinische Klinik und Poliklinik III am Klinikum der LMU München 8Department I of Internal Medicine and Cologne Interventional Immunology and Medizinische Klinik und Poliklinik III (J.C.H., M.v.B.-B.), University Hospital Ludwig-Maximilian University Munich, Germany.; German Cancer Consortium (DKTK), Munich (J.C.H., M.v.B.-B.). Department of Medicine III, University Hospital, Ludwig Maximilian University (LMU) Munich, Munich, Germany;; German Cancer Consortium, Munich Site, and German Cancer Research Center, Heidelberg, Germany; Department of Medicine III, University Hospital, LMU Munich, Germany 1Department I of Internal Medicine, Center for Integrated Oncology (CIO), University Hospital of Cologne, Cologne, Germany.; 2Cologne Interventional Immunology, Department I of Internal Medicine, University Hospital of Cologne, Germany.; 4Radio-Immuno-Oncology (RIO) Initiative, University Hospital of Cologne, Cologne, Germany. Department of Medicine III, University Hospital, LMU Munich, München, Germany Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; Comprehensive Cancer Center Munich (CCCM), Munich, Germany; Cologne Interventional Immunology, Department I of Internal Medicine, University of Cologne, Cologne, Germany; Center for Molecular Medicine Cologne, Cologne, Germany Internal Medicine III - Hematology/Oncology; University Hospital Munich; Munich Germany Medizinische Klinik und Poliklinik III, Klinikum der LMU München, Deutschland; Intensive Care in Hematologic and Oncologic Patients (iCHOP) Department of Internal Medicine I, University of Cologne, Cologne, Germany. 1Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany; 3German Cancer Consortium (DKTK), partner site Munich, Munich, Germany; 4Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany Cologne Interventional Immunology, University of Cologne, Cologne, Germany; Department I of Internal Medicine (Hematology/Oncology), University of Cologne, Cologne, Germany Department I of Internal Medicine, University Hospital of Cologne, 50937 Cologne, Germany Radio Immune-Oncology Consortium (RIO), University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology (CIO) Cologne Bonn, University Hospital Cologne, Cologne, Germany; Department I of Internal Medicine, Hematology & Oncology, University Hospital Cologne, Cologne, Germany Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany; and German Cancer Consortium (DKTK), Partner Site Munich, Germany; Department of Medicine, Hematology & Oncology Division and Cellular Immunotherapy Program, Ludwig-Maximilians-University School of Medicine, Munich, Germany Department of Medicine III, Ludwigs-Maximilians-Universität (LMU) Munich and Comprehensive Cancer Center (CCC) /German Cancer Consortium (DKTK)/Bayerisches Zentrum für Krebsforschung (BZKF), Munich, Germany; and Department of Medicine III – Hematology/Oncology, University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), Munich and Berlin sites, and German Cancer Research Center, Heidelberg, Germany.; Bavarian Cancer Research Center (BZKF), partner sites, Munich and Erlangen, Germany. Cologne Interventional Immunology (CII), Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, D-50924 Cologne, Germany |
Incoming Links
Total number of triples: 304.